Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL Amyloidosis

Immix Biopharma announced positive results from its Phase 1/2 NEXICART-2 clinical trial of NXC-201, a sterically-optimized BCMA-targeted CAR-T cell th...
Home/KnloSights/Clinical Trial Updates/Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL Amyloidosis